CS1 is a member of the signaling lymphocyte activation molecule (SLAM) family that is widely expressed in human plasma and myeloma cells, making it a promising target for immunotherapy in multiple myeloma (MM). Here, SLAMF7 is linked to Miyoshi myopathy.